Traders are feeling more bearish on shares of the company if you take into consideration the change in short interest. The company realized a rise in short interest from September 29, 2017 to October 13, 2017 of 37.76%. Short shares increased from 96,246 to 132,585 over that timeframe. With short interest at 132,585 and short average daily volume at 79,913, days to cover is 2.0 and the percentage of shorted shares was 0.00% on October 13.
These firms have modified their investment in ALQA. Janney Montgomery Scott LLC downsized its holdings by shedding 4,000 shares a decrease of 4.4% in the quarter. Janney Montgomery Scott LLC now controls 87,500 shares worth $32,000. The value of the position overall is down by 30.4%. Chicago Partners Investment Group LLC trimmed its position by selling 6,442 shares a decrease of 99.8%. Chicago Partners Investment Group LLC now holds 11 shares valued at $0. The total value of its holdings decreased 100.0%.
Kcg Holdings, Inc. reduced its ownership by shedding 63,555 shares a decrease of 12.1% from 03/31/2017 to 06/30/2017. Kcg Holdings, Inc. claims 461,522 shares with a value of $171,000. The value of the position overall is down by 35.5%. As of the end of the quarter Sabby Management, LLC had sold a total of 1,059,641 shares trimming its holdings by 49.7%. The value in dollars decreased from $1,076,000 to $396,000 a change of 63.2% quarter to quarter.
In the market the company is trading up by 1.24% percent from yesterday’s close. The stock last traded at $3.26 which is a tad under the 50 day moving average of $3.32 and a tad below the 200 day moving average of $3.54. The 50 day moving average was down $-0.06 or -1.77% and the 200 day average went down $-0.28 or -7.89%.
As of the latest earnings report the EPS was $-11.16 and is estimated to be $-3.55 for the current year with 5,010,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.60 with next year’s EPS anticipated to be $-1.70.
Alliqua BioMedical, Inc., launched on April 15, 2014, is a provider of wound care solutions. The Company operates in commercial wound care segment, which consists of approximately five product categories, such as Wound Bed Preparation & Stimulation; Human Biologics; Antimicrobial Protection; Exudate Management, and Contract Manufacturing. The Company has a suite of wound care solutions that enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company has built its portfolio through its hydrogel technology platform, targeted acquisitions, and through licensing and distribution agreements. Its contract manufacturing business provides custom hydrogels to the original equipment manufacturer (OEM) market..